Modeling NASH and NASH-Induced Hepatocellular Carcinoma: Faster and Better
نویسندگان
چکیده
منابع مشابه
Surveillance for Hepatocellular Carcinoma in Patients with NASH
European and American guidelines recommend surveillance for hepatocellular carcinoma (HCC) by performing ultrasonography on a six-month basis on an at risk population, defined by presence of cirrhosis. HCC, due to non-alcoholic steatohepatitis (NASH), is rising. Patients with NASH have a high risk of developing HCC and, therefore, have to be enrolled in a screening program. One of the challenge...
متن کاملBetter and Faster Patient Training
اقامت هرچه کوتاهتر بیمار در بیمارستان، مستلزم آموزش مؤثر او و خانواده وی است
متن کاملMolecular and Cellular Pathobiology Proteomic and Lipidomic Signatures of Lipid Metabolism in NASH-Associated Hepatocellular Carcinoma
Nonalcoholic steatohepatitis (NASH) is a commonpreneoplastic condition of hepatocellular carcinoma (HCC). Mice with hepatocytic deletion of Pten develop NASH and HCC later in life. This model is highly valuable for studies aimed at identifying the molecular mechanism by which metabolic disorders contribute to tumor development. We applied proteomic and lipidomic profiling approaches to Pten-nul...
متن کاملStochastic Coalitional Better-response Dynamics and Strong Nash Equilibrium
We consider coalition formation among players in an n-player finite strategic game over infinite horizon. At each time a randomly formed coalition makes a joint deviation from a current action profile such that at new action profile all players from the coalition are strictly benefited. Such deviations define a coalitional better-response (CBR) dynamics that is in general stochastic. The CBR dy...
متن کاملMidkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma
UNLABELLED Robust biomarkers for population-level hepatocellular carcinoma (HCC) surveillance are lacking. We compared serum midkine (MDK), dickkopf-1 (DKK1), osteopontin (OPN) and AFP for HCC diagnosis in 86 HCC patients matched to 86 cirrhotics, 86 with chronic liver disease (CLD) and 86 healthy controls (HC). Based on the performance of each biomarker, we assessed a separate longitudinal coh...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cellular and Molecular Gastroenterology and Hepatology
سال: 2021
ISSN: 2352-345X
DOI: 10.1016/j.jcmgh.2021.05.015